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http://www.diagnosticpathology.org/content/7/1/143CASE REPORT Open AccessPrimary splenic histiocytic sarcoma complicated
with prolonged idiopathic thrombocytopenia and
secondary bone marrow involvement: a unique
surgical case presenting with splenomegaly but
non-nodular lesions
Sohsuke Yamada1*, Takashi Tasaki11, Naoko Satoh1,2, Atsunori Nabeshima1, Shohei Kitada1,3, Hirotsugu Noguchi1,
Kozue Yamada4, Morishige Takeshita4 and Yasuyuki Sasaguri1Abstract: A 67-year-old Japanese female was followed up due to prolonged idiopathic thrombocytopenia with
non-response to steroid therapy for 4 years, but recent progressive pancytopenia, hypo-albuminemia, and
hypo-γ-globulinemia were presented. An abdominal CT scan revealed heterogeneously enhanced splenomegaly
without any nodular lesions. A splenectomy was performed, and gross examination showed markedly hyperemic
red pulp, weighing 760 g, accompanied by multiple foci of peripheral anemic infarction. Surprisingly, microscopic
findings exhibited a diffuse proliferation of medium-sized to large tumor cells having pleomorphic nuclei,
prominent nucleoli, and abundant eosinophilic cytoplasm, predominantly within the sinuses and cords of the red
pulp, which occasionally displayed conspicuous hemophagocytosis and vascular permeation. In
immunohistochemistry, these atypical cells were specifically positive for CD68 (KP-1), CD163, and lysozyme, which
was consistent with histiocytic sarcoma (HS) of the spleen. Subsequently, section from the aspiration of bone
marrow showed infiltration of the neoplastic cells associated with erythrophagocytosis 2 months after the
operation, but never before it. Therefore, primary splenic HS presenting with secondary bone marrow involvement
was conclusively diagnosed. Since early diagnosis and treatment are necessary for the HS patients with poor
outcomes, splenic HS should be considered as a differential diagnosis in cases with chronic thrombocytopenia and
splenomegaly.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1009474924812827
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By definition, histiocytic sarcoma (HS), a rare
hematopoietic neoplasm, but a known entity, represent-
ing as less than 0.5% of all non-Hodgkin’s lymphoma, is
malignant proliferation of cells presenting morphologic
and immunophenotypic characteristics of mature tissue
histiocytes [1,2]. HS is known to often present as loca-
lized disease confined to the intestinal tract, skin, lymph* Correspondence: sousuke@med.uoeh-u.ac.jp
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reproduction in any medium, provided the ornode, or soft tissues [1-3], however, primary HS of the
spleen has been an exceedingly rare. Mathé G et al. first
proposed the term ‘HS’ tentatively in 1970 [4]. In con-
trast, since its description was strictly based on the
histologic similarities of the tumor cells to macrophages,
this diagnostic challenge is further complicated as it is
critical to clearly distinguish HS from other histiocytic
processes, from benign to malignant, such as hemopha-
gocytic syndrome, malignant histiocytosis, and acute
monocytic leukemia [5-7]. Despite that, the detailed
evaluation of HS depends especially on the verification
of histiocytic lineage and the exclusion of otherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yamada et al. Diagnostic Pathology 2012, 7:143 Page 2 of 7
http://www.diagnosticpathology.org/content/7/1/143malignancies, including anaplastic large cell lymphoma,
diffuse large B-cell lymphoma, poorly differentiated car-
cinoma, malignant melanoma, follicular dendritic cell
sarcoma, or interdigitating dendritic cell sarcoma, by
way of thorough immunohistochemical examination [1-
3,8,9]. In this context, it is very difficult to interpret HS
papers published more than 25 years ago, i.e., before the
development and widespread use of immunohistochem-
ical techniques and the availability of molecular genetic
tools [3]. Actually, until now, the number of ‘true’ cases
reported as primary splenic HS in the English literatures
is only few, up to 7, and most recent references are from
2008 within our investigation [10-14], summarized in
Table 1, and its clinicopathological features have not
been well described. Based on this Table 1, HS of the
spleen can be potentially lethal condition that might re-
main asymptomatic or closely related with chronic
thrombocytopenia for a long time [11-13]. Even while
diagnostic imaging findings have not been also charac-
terized satisfactorily, primary splenic HS cases often
show multi-nodular or nodular lesions in the enlarged
tissues of spleen [10-14]. The patients of splenic HS have
a poor prognosis due to aggressive behavior with liver or
bone marrow infiltration, even though a splenectomy
might induce temporary remission [11,14]. Therefore,
early accurate diagnosis and treatment before dissemi-
nated proliferation of the HS tumor cells should improve
their survival rates.
Indeed, this is not the first case reported. Despite
that, we reported a very rare and unique surgical case
of primary splenic HS complicated with prolonged
idiopathic thrombocytopenia, progressive pancytopenia,
hypo-albuminemia, hypo-γ-globulinemia, and secondary
bone marrow involvement, which grossly presented as
splenomegaly with multiple peripheral infarction but
without any nodular foci.
Materials and methods
The patient was a 67-year-old Japanese female. The spe-
cimen after fixation in 10% neutral buffered formalin
was embedded in paraffin for histological orTable 1 Comparison of the main clinical features among the r
Case [reference] Age Sex CC Imaging or Gross f
1 [10] 38 m Weakness multinodula
2 [11] 29 m edema nodular
3 [11] 60 m thrombocytopenia nodular
4 [11] 66 f edema, anemia multinodlar
5 [12] 71 f thrombocytopenia multinodlar
6 [13] 82 f Evans syn, multinodula
7 [14] 58 f anemia nodular
Present case 67 thrombocytopenia non-nodula
CC chief complaint, S surgery (splenectomy), R radiation, C chemotherapy, Y year, Mimmunohistochemical examinations. All immunohisto-
chemical stainings were carried out using Dako Envision
kit (Dako Cytomation Co., Glostrup, Denmark) accord-
ing to the manufacturer’s instructions, and using com-
mercially available prediluted monoclonal antibodies
against the following antigens: CD1a (Immuno Tech.
Co., Ltd., Osaka, Japan, diluted 1:2), CD3 (Dako, diluted
1:1), CD4 (Dako, diluted 1:1), CD5 (NOVOCASTRA la-
boratories Ltd., Newcastle, United Kingdom, diluted
1:25), CD8 (Nichirei Biosciences Inc., Tokyo, Japan,
diluted 1:1), CD10 (NOVOCASTRA, diluted 1:20),
CD20 (Dako, diluted 1:200), CD21 (Dako, diluted 1:10),
CD23 (Nichirei, diluted 1:1), CD30 (Dako, diluted 1:40),
CD45 (Dako, diluted 1:400), CD45RO (UCHL-1; Dako,
diluted 1:200), CD68 (KP-1; Dako, diluted 1:100), CD79a
(Dako, diluted 1:50), CD163 (Leica Microsystems, Wet-
zlar, Germany, diluted 1:200), lysozyme (Dako, diluted
1:600), S-100 protein (Dako, diluted 1:900), fascin (Dako,
diluted 1:50), bcl-2 (Dako, diluted 1:30), myeloperoxi-
dase (MPO; Dako, dilutede 1:500), EMA (Dako, diluted
1:100), Cam5.2 (Becton Dickinson Immunocytometry
Systems, San Jose, CA, diluted 1:1), and HMB45 (Enzo
Life Sciences Ltd., New York, diluted 1:100). Epstein-
Barr virus (EBV) infection status was analyzed by in situ
hybridization for EBV-encoded RNAs using an Epstein-
Barr Early RNA Probe Reagent (EBER; Roche Applied
Science, Lewes, UK). However, no chromosome studies
have been performed.
Case presentation
This patient had 4-year-history of idiopathic
thrombocytopenia with non-response to steroid therapy
and progressive pancytopenia half year before a splenec-
tomy (Figure 1A). There was no history of immunosup-
pressive disorders, use of immunosuppressive medications,
or unusual infections. The abdominal CT scanning
showed heterogeneously enhanced and growing spleno-
megaly without evidence of mass or nodular lesions,
measured approximately 130 × 80 mm in diameter
(Figure 1B). Retrospectively, the clinical imaging examin-
ation also demonstrated mild splenomegaly, measuredeported cases with primary splenic HS, including ours
eatures Weight of spleen Therapy Prognosis Involvement
r 264 g S - -
735 g S(R+C) 5Y1M Liver
610 g S+C 1Y6M Liver, BM
750 g R+S+C 2Y6M Liver, BM
470 g C 6 M Hilum LN
r 110 g R 1 M Liver
800 g R+S+C 3 M -
760 g S 6 M BM
month, BM bone marrow, LN lymph node.
Figure 1 Summary of various clinical data before and after splenectomy, and the finding of an abdominal CT scan at surgery. (A) This
patient showed prolonged idiopathic thrombocytopenia presenting with increased splenomegaly and non-response to steroid therapy. In
addition, progressive pancytopenia, hypo-albuminemia, and hypo-γ-globulinemia coexisted. (B) The abdominal CT scanning revealed
heterogeneously enhanced, severe splenomegaly without evidence of mass or nodular lesions.
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before surgery, respectively (Figure 1A). In laboratory
data on admission, blood cell counts revealed pancyto-
penia; white blood cell count (WBC) was 1,300/mm3;
hemoglobin (Hb) was 5.7 g/dL; and platelet count (Plt)
was 8,000/mm3 (Figure 1A). Biochemistry showed almost
within normal limits, except for low levels of total
protein (TP; 4.9 g/dL), albumin (Alb; 1.6 g/dL), and
γ-globulin (γ-gl 0.6 g/dL) (Figure 1A), whereas high level
of C-reactive protein (CRP; 4.07 mg/dL). Serum interleu-
kin 2 receptor (sIL-2R) level as a tumor marker was only
increased up (1306.0 U/mL). Physical examination on
admission demonstrated no remarkable change, except
for mild weakness. Since the clinician highly suspected
hypersplenism, a splenectomy was performed. The pa-
tient was dead due to secondary bone marrow involve-
ment of the HS tumor cells, as described more in
detail below. Autopsy could not be examined because
of the family’s objection. The clinical findings including
laboratory examination and therapy for 4 years are
summarized in Figure 1A until his death 6 months
after the surgery.Pathological findings
Before the operation, the clinician and we pathologists
had performed and examined bone marrow aspiration 5
times for 2 and half years (September in 2009, Septem-
ber and December in 2010, December in 2011, and Janu-
ary in 2012), histologically showing the tissues of
normo- to hyper-cellular marrow (cellularity: 50-70%)
composed of 3 series of hematopoietic cells with a
mildly increasing number of bland-looking megakaryo-
cytes (4-8/1HPF). There was no evidence of monotonousproliferation of atypical or blastoid cells in the bone
marrow specimens (not shown).
On gross examination of the surgical specimen, the
spleen was markedly enlarged, measuring 145 × 120 ×
80 mm and weighing 760 g. The cut surface revealed
multiple foci of peripheral infarction but not mass or
nodular lesions, which predominantly looked dark-red in
colour associated with congestive red pulp and depleted
white pulp (Figure 2). A scanning magnification of it
showed markedly hyperemic red pulp, coexisted with
peripheral anemic infarcts and hemorrhage, but not
encapsulated tumor-like lesions (not shown).
Microscopically, the spleen predominantly displayed a
diffuse proliferation of medium-sized to large tumor
cells having mildly hyperchromatic and pleomorphic nu-
clei, prominent nucleoli, and abundant eosinophilic or
clear cytoplasm, mainly within the sinuses and cords of
the red pulp, highlighted by silver impregnation
(Figure 3A). However, neither nodular lesions nor fi-
brous encapsulation were evident with Masson’s tri-
chrome staining (data not shown). On high-power view,
these large cells occasionally showed apparent hemopha-
gocytosis of red blood cells or mononuclear lymphocytes
(Figure 3B). Hemosiderin pigments in the hemophagocy-
tic tumor cells confirmed erythrophagocytosis with
Berlin-blue staining (Figure 3B). On the other hand, vas-
cular invasion of the tumor cells was sometimes noted
in the trabecular artery, making a clear contrast by elas-
tica van Gieson (EVG) staining (Figure 3C). It was sug-
gested that vascular permeation could induce multiple
foci of peripheral anemic infarction associated with
hemorrhage. Additionally, adjacent to these infarcts, a
very small amount of the existing splenic tissue was re-
markably compressed. In immunohistochemistry, these
Figure 2 Gross examination of splenic HS from the resected
specimen. On gross examination of the splenomegaly, the cut
surface showed multiple foci of peripheral anemic infarction, but not
any mass or nodular lesions, which predominantly looked dark-red
in colour associated with congestive red pulp and depleted white
pulp. Bar = 10 mm.
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(Figure 4A), CD163 (Figure 4B), lysozyme (Figure 4C),
S-100 protein, and CD45, and many reactive histiocytes
were also positive for CD163 and S-100 protein.
Whereas, the tumor cells were negative for CD1a, CD3,
CD4, CD5, CD8, CD10, CD20, CD21, CD23, CD30,
CD45RO (UCHL-1), CD79a, fascin, bcl-2, myeloperoxi-
dase (MPO), EMA, Cam5.2, and HMB45. All immuno-
histochemical profile of the tumor cells is summarized
in Table 2. By contrast, CD8 staining confirmed that
proliferating tumor cells were existed within the sinuses
and cords of the red pulp, accompanied focally by the
destruction of the sinuses (data not shown). On the
other hand, in situ hybridization for EBV-encoded RNAs
was negative. Based on all these features, we made a
diagnosis of histiocytic sarcoma (HS) of the spleen.Furthermore, 2 months after the splenectomy, the HS
cells partially infiltrated the bone marrow (Figure 5A),
coexisting with a substantial amount of 3 series of nor-
mocellular marrow including a significantly increasing
number of megakaryocytes. Immunohistochemical CD68
(Figure 5B) and S-100 protein stainings could make it
much easier to understand the microscopic findings of
HS involvement in the bone marrow. The above clinical
and pathological findings indicated that this case was
really primary splenic HS presenting with secondary
bone marrow involvement.
Discussion
It is possible that the current case report might be
pathologically remarkable for two reasons at least: first,
neither nodular formation nor fibrous encapsulation was
evident in the tissue of spleen appearing as splenomeg-
aly. According to the several case reports of primary HS
of the spleen as summarized in Table 1, all tumors have
macroscopically exhibited nodular or multi-nodular
lesions with or without fibrous encapsulation, composed
of a diffuse proliferation of HS cells predominantly in a
sinusoidal pattern within the red pulp [1], very similar to
our case. However, this case showed that the existing
splenic tissue was significantly small and compressed, in-
ducing these characteristic imaging and gross features
(Figures 1 and 2), possibly compared to the other splenic
HS cases [10-14]. Although we cannot provide the direct
evidence that the present splenic HS shows only spleno-
megaly, future studies will be further required to deter-
mine how its mechanism has a role in the tumor growth
after collecting and examining a larger number of
splenic HS cases. Second, multiple foci of peripheral
anemic infarction coexisted. It is well known that vascu-
lar invasion is a common finding in high grade malig-
nancies, frequently associated with thrombosis and
ischemia, i.e., ischemic necrosis (infarction). In spite of
that, merely one splenic HS case has demonstrated rela-
tively large necrosis due to an infarction of the splenic
artery [11], as likely shown in Figure 3. As described
here (Table 1), splenic HS has an extensively aggressive
behavior with vessel permeation and a poor prognosis,
regardless of the localized site of tumor origin. Actually,
another autopsy case of HS (but entitled ‘malignant his-
tiocytosis’ in the published paper) with unknown pri-
mary site demonstrated that the mechanical pressure
elicited by severe infiltration of HS cells in the spleen
should lead to capsular weakening and splenic rupture
[15].
Some confusion still exists even in the recent literature
with regard to the terminology of this entity, i.e., histio-
cytic lymphoma, malignant histiocytosis, or HS. Despite
that, the term HS includes whole spectrum of localized
and disseminated forms from true histiocytic lymphoma
AC
B
Figure 3 Histological examination of splenic HS. (A) The spleen predominantly showed a diffuse proliferation of medium-sized to large tumor
cells having mildly hyperchromatic and pleomorphic nuclei, prominent nucleoli, and abundant eosinophilic or clear cytoplasm, mainly within the
sinuses and cords of the red pulp, highlighted by silver impregnation (inset) (H&E stains, Original magnification × 200). (B) On high-power view,
these large tumor cells exhibited apparent hemophagocytosis of red blood cells or mononuclear lymphocytes (H&E stains, Original magnification
× 400). Hemosiderin pigments within the large cells confirmed erythrophagocytosis by Berlin-blue staining (inset). (C) Vascular invasion of these
tumor cells was noted in the trabecular artery, very likely inducing multiple foci of peripheral anemic infarction (H&E stains, Original magnification





Figure 4 Immunohistochemical examination for the tumor cells of splenic HS. (A)(B)(C) These large tumor cells were specifically positive for
CD68 (KP-1) (A), CD163 (B), and lysozyme (C), and many reactive histiocytes were also positive for CD163 (Original magnification × 400).
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Table 2 Immunohistochemical profile of the tumor cells
in our splenic HS case
positive negative
CD68 (KP-1) CD1a CD30
CD163 CD3 CD45RO
lysozyme CD4 CD79a
S-100 protein CD5 fascin
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context, it is very challenging that we pathologists
strictly make a final disgnosis as primary splenic HS,
since many HS cases have exhibited extensive involve-
ment of other organs at first decision, representing as
dissemination of tumor cells, such as the above splenic
rupture case [15]. Indeed, so-called ‘malignant histiocy-
tosis’ has considered to be apparently characterized by
general symptoms including high fever, wasting, lymph-
adenopathy, hepatosplenomegaly, and progressive pan-
cytopenia, resulting in a rapidly fatal clinical outcome,
rather than localized form of HS [11,15]. Moreover, it is
likely that well-defined nodular lesions are very rare in
most of the ‘malignant histiocytosis’ cases [11], as in the
present splenic HS. In this context, the present case
seems to be categorized into classical ‘malignant histio-
cytosis’, rather than so-called true ‘histiocytic lymphoma’.
Nevertheless, splenic HS must be a unique clinicalFigure 5 Histological and immunohistochemical examination of
secondary bone marrow involvement of primary splenic HS.
2 months after the splenectomy, the tumor cells infiltrated the bone
marrow tissue (H&E stains, Original magnification × 200).
Immunohistochemical CD68 staining (inset) could make it much
easier to understand the microscopic findings of HS involvement in
the bone marrow.entity, particularly associated with hypo-albuminemia,
hypo-γ-globulinemia, and thrombocytopenia [11-13].
Ezdinli EZ et al. [16] proposed that, as to those mechan-
isms, the neoplastic histiocytes could phagocytose albu-
min and immunoglobulin as well as blood cells,
pathologically manifesting as hemophagocytic syndrome,
as shown in Figure 3B. On the other hand, HS is very
likely an uncertain neoplasm from the aspects of mo-
lecular pathogenesis. Although no cytogenetic studies
have been performed here, some recent papers demon-
strated a clonal immunoglobulin heavy chain gene re-
arrangement [17,18], a clonal cytogenetic abnormality
including t(14;18) [17], and a 57–80 hyperdiploid [7]/46,
XY [13] karyotype, including 3 to 4 copies of various
chromosomes [8]. Further studies are needed. It also
remains to be elucidated whether splenectomy with or
without following aggressive chemotherapy is beneficial
for patients with splenic HS or not, since it has been
reported that so-called ‘malignant histiocytosis’ has no
or little response to splenectomy [19]. In fact, based on
the current Table 1, HS of the spleen must be potentially
lethal condition with short survival even after the splen-
ectomy combined with chemotherapy and irradiation.
Pathological differential diagnoses of this splenic HS
case include interdigitating dendritic cell sarcoma, fol-
licular dendritic cell sarcoma, Langerhans cell sarcoma,
diffuse large B-cell lymphoma, peripheral T-cell lymph-
oma, anaplastic large cell lymphoma, metastatic carcin-
oma, and malignant melanoma. Morphologically, tumor
cells in interdigitating dendritic cell sarcoma, follicular
dendritic cell sarcoma, and Langerhans cell sarcoma
often have grooved, indented, folded, lobulated, or oval-
to spindle-shaped nuclei, arranged in a nodular, fascicu-
lar, or storiform growth pattern, that should be absent in
HS [1-3,8,9]. The conclusive diagnosis of HS is based on
not only histological but immunohistochemical examin-
ation of histiocytic differentiation and exclusion of other
immunophenotypes including lymphoid, epithelial, or
melanocytic differentiation, as also described here (Table
2). The tumor cells in the present case apparently
revealed positive expression of specific histiocytic mar-
kers, such as CD68 (KP-1), and lysozyme (Figure 4). But
these HS cells also diffusely expressed the hemoglobin
scavenger marker, CD163, regarded as a peculiar marker
for HS as well [20].
Conclusion
We herein reported a unique surgical case of primary
splenic HS strongly associated with pathological findings
of aggressive infiltration of tumor cells in the red pulp
and splenic artery, in the background of splenomegaly
with multiple foci of anemic infarction, but without any
nodular lesions. Although splenic HS is very uncommon,
not only clinicians but we pathologists should be aware
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prognosis, and must consider it as a differential diagno-
sis in cases with prolonged thrombocytopenia with
splenomegaly that is non-responsive to therapy.
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